Physician profile
Cindy Lam
NPI 1881267011
$2,000.76
in general payments reported to CMS, 2019-2025
14 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $369 · 2023: $834 · 2024: $507 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,238 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,237.72 |
| Education | $268.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $817.65 | 2022-2025 | Kisqali |
| Daiichi Sankyo INC. | $213.35 | 2023 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $205.62 | 2021-2024 | Enhertu |
| Incyte Corporation | $169.94 | 2023-2024 | |
| Mirati Therapeutics, INC. | $125.00 | 2023 | Krazati |
| Janssen Biotech, INC. | $125.00 | 2022 | |
| Gilead Sciences, INC. | $123.40 | 2024-2025 | Trodelvy |
| Silk Road Medical, INC. | $65.38 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Celgene Corporation | $56.90 | 2023-2024 | Pomalyst, Reblozyl |
| Stemline Therapeutics INC. | $31.81 | 2023 | Orserdu |
| Glaxosmithkline, LLC. | $20.38 | 2024 | Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $16.54 | 2024 | |
| Alexion Pharmaceuticals, INC. | $16.37 | 2024 | Ultomiris |
| Vapotherm INC | $13.42 | 2023 | Vapotherm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.